4.74
Nuvation Bio Inc stock is traded at $4.74, with a volume of 1.97M.
It is up +1.28% in the last 24 hours and down -18.28% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$4.68
Open:
$4.74
24h Volume:
1.97M
Relative Volume:
0.29
Market Cap:
$1.66B
Revenue:
$143.05M
Net Income/Loss:
$-145.99M
P/E Ratio:
-11.07
EPS:
-0.4282
Net Cash Flow:
$-134.06M
1W Performance:
-4.24%
1M Performance:
-18.28%
6M Performance:
-1.66%
1Y Performance:
+25.73%
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
NUVB
Nuvation Bio Inc
|
4.74 | 1.66B | 143.05M | -145.99M | -134.06M | -0.4282 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.74 | 129.20B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.26 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
849.01 | 53.39B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-26 | Initiated | Citigroup | Buy |
| Aug-21-26 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-18-26 | Initiated | JP Morgan | Overweight |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
3 Promising Penny Stocks With Market Caps Over $200M - Simply Wall Street
Nuvation Bio Inc. (NUVB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Nuvation Bio Inc. (NUVB) stock price, news, quote and history - Yahoo Finance Singapore
Nuvation Bio Inc. (NUVB) stock price, news, quote and history - Yahoo Finance UK
What Makes Nuvation Bio (NASDAQ:NUVB) Stand Out in Nasdaq Biotech? - Kalkine Media
Elite Penny Stocks To Watch In October 2026 - Simply Wall Street
Citigroup Initiates Nuvation Bio at Buy With $12 Price Target - Moomoo
Nuvation stock, Jazz stock gain new Buys at Citi (NUVB:NYSE) - Seeking Alpha
Citigroup Initiates Nuvation Bio at Buy With $12 Price Target - Yahoo Finance
Nuvation Bio Inc. (NUVB): Investor Outlook With A 115.82% Potential Upside - DirectorsTalk Interviews
Why Is Nuvation Bio Stock Gaining Thursday? - Benzinga
Nuvation Bio stock gains on FDA label update for IBTROZI - Investing.com
Nuvation Bio Inc. (NUVB) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
Nuvation Bio stock rises on Ibtrozi label update (NUVB:NYSE) - Seeking Alpha
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer - PR Newswire
Nuvation Bio Inc. (NYSE:NUVB) Wins FDA OK To Add ~50-Month DOR To IBTROZI Label - TradingView
Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups - Yahoo Finance
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - PR Newswire
Nuvation Bio (NUVB) Stock Looks Stretched Despite Its 354% Three Year Run - webull.com
NUVB: IBTROZI dominates ROS1 with best-in-class efficacy, while safusidenib advances across glioma subtypes - TradingView
Nuvation Bio at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline gains - Investing.com
NUVB: IBTROZI’s superior efficacy and safety drive rapid market share gains, with a strong pipeline advancing - TradingView
Nuvation Bio at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline gains - Investing.com Canada
Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com Canada
Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com UK
NUVB: IBTROZI and safusidenib drive growth with best-in-class efficacy and expanding global opportunities - TradingView
NUVB: IBTROZI and safusidenib drive strong growth, with major clinical and commercial milestones ahead - TradingView
Jim Cramer sends strong 5-word message on surging biotech stock - Yahoo Finance
Jim Cramer sends strong 5-word message on surging biotech stock - thestreet.com
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is... - Benzinga
Cramer's lightning round: Nuvation Bio 'is a pure spec' - CNBC
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Yahoo Finance
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Zacks Investment Research
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
Nuvation Bio to Participate in Upcoming Investor Conferences - PR Newswire
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why - Yahoo Finance
Nuvation Bio downgraded to Hold after 200% rall... - Pluang
NUVB|Nuvation Bio Inc|Price:7.100|Chg%:+0.340 - TradingKey
Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com UK
Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com
Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvation Bio Inc Stock (NUVB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER |
Aug 19 '26 |
Sale |
7.09 |
100,000 |
709,240 |
0 |
| GARY HATTERSLEY | Officer |
Aug 19 '26 |
Proposed Sale |
6.96 |
100,000 |
696,000 |
0 |
| Sauvage Philippe | Chief Financial Officer |
Jul 15 '26 |
Option Exercise |
2.17 |
40,000 |
86,800 |
54,131 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Option Exercise |
2.93 |
63,000 |
184,590 |
116,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Sale |
6.02 |
63,000 |
379,191 |
53,000 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Option Exercise |
2.17 |
47,668 |
103,440 |
60,341 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Sale |
6.01 |
47,668 |
286,370 |
12,673 |
| STACY MARKEL | Officer |
Jun 23 '26 |
Proposed Sale |
5.76 |
125,000 |
720,000 |
0 |
| KERRY WENTWORTH | Officer |
Jun 23 '26 |
Proposed Sale |
5.76 |
63,000 |
362,880 |
0 |
| PHILIPPE SAUVAGE | Officer |
Jun 23 '26 |
Proposed Sale |
5.76 |
47,668 |
274,568 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):